AIkido Pharma (NASDAQ:AIKI) Shares Cross Above 200 Day Moving Average of $2.23

AIkido Pharma Inc. (NASDAQ:AIKI) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.23 and traded as high as $3.00. AIkido Pharma shares last traded at $2.93, with a volume of 20,966 shares changing hands.

AIkido Pharma Price Performance

The stock has a fifty day moving average price of $2.30 and a 200-day moving average price of $2.23. The company has a market cap of $15.36 million, a PE ratio of -0.76 and a beta of 0.93.

Institutional Trading of AIkido Pharma

A number of hedge funds have recently modified their holdings of AIKI. Jane Street Group LLC raised its holdings in shares of AIkido Pharma by 247.4% during the first quarter. Jane Street Group LLC now owns 100,096 shares of the business services provider’s stock worth $45,000 after acquiring an additional 71,284 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of AIkido Pharma by 26.5% during the third quarter. Dimensional Fund Advisors LP now owns 57,849 shares of the business services provider’s stock worth $396,000 after acquiring an additional 12,111 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of AIkido Pharma during the third quarter worth $367,000. Finally, Two Sigma Advisers LP raised its holdings in shares of AIkido Pharma by 630.0% during the third quarter. Two Sigma Advisers LP now owns 86,700 shares of the business services provider’s stock worth $593,000 after acquiring an additional 74,824 shares in the last quarter. Hedge funds and other institutional investors own 10.88% of the company’s stock.

About AIkido Pharma

AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.